We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.29B
AUM Growth
-$158M
Cap. Flow
-$42M
Cap. Flow %
-1.83%
Top 10 Hldgs %
41.8%
Holding
210
New
13
Increased
53
Reduced
56
Closed
18

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$16.6M
2
ILMN icon
Illumina
ILMN
+$12.9M
3
HUM icon
Humana
HUM
+$10.1M
4
BIIB icon
Biogen
BIIB
+$7.74M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.7M
2
ABT icon
Abbott
ABT
+$15.4M
3
ARRY
Array Biopharma Inc
ARRY
+$15M
4
TMO icon
Thermo Fisher Scientific
TMO
+$13.4M
5
LLY icon
Eli Lilly
LLY
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Real Estate 3.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
176
DELISTED
Merus
MRUS
$382K 0.02%
21,421
-223,693
-91% -$3.67M
ZYME icon
177
Zymeworks
ZYME
$1.67B
$377K 0.02%
+15,192
New +$381K
CDTX
178
DELISTED
Cidara Therapeutics
CDTX
$317K 0.01%
7,939
– –
TECX
179
Tectonic Therapeutic
TECX
$538M
$285K 0.01%
+1,681
New +$381K
TTPH
180
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$229K 0.01%
42,966
– –
ITCI
181
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$206K 0.01%
27,548
-27,548
-50% -$264K
ORKA
182
Oruka Therapeutics
ORKA
$5.9B
$192K 0.01%
3,006
– –
WHWK
183
Whitehawk Therapeutics
WHWK
$190M
$175K 0.01%
17,170
-32,163
-65% -$356K
DNTH icon
184
Dianthus Therapeutics
DNTH
$6.16B
$172K 0.01%
+1,047
New +$199K
NVAX icon
185
Novavax
NVAX
$1.22B
$143K 0.01%
28,550
– –
TRIL
186
DELISTED
Trillium Therapeutics Inc.
TRIL
$137K 0.01%
446,099
– –
ADAP
187
DELISTED
Adaptimmune Therapeutics
ADAP
$116K 0.01%
77,061
-151,435
-66% -$354K
CLSD
188
DELISTED
Clearside Biomedical
CLSD
$104K ﹤0.01%
11,022
– –
MNK
189
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$79K ﹤0.01%
32,980
– –
BLCM
190
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$63K ﹤0.01%
6,000
– –
QHC
191
DELISTED
Quorum Health Corporation
QHC
$29K ﹤0.01%
23,725
– –
CLDX icon
192
Celldex Therapeutics
CLDX
$3.02B
$15K ﹤0.01%
7,053
– –
AFMD
193
DELISTED
Affimed
AFMD
– –
-25,400
Closed -$729K
LIVN icon
194
LivaNova
LIVN
$4.45B
– –
-45,681
Closed -$3.29M
PTGX icon
195
Protagonist Therapeutics
PTGX
$8.92B
– –
-121,341
Closed -$1.47M
RYTM icon
196
Rhythm Pharmaceuticals
RYTM
$7.25B
– –
-24,890
Closed -$548K
SGMO
197
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-120,768
Closed -$1.3M
TXMD icon
198
TherapeuticsMD
TXMD
$23.5M
– –
-10,836
Closed -$1.41M
VKTX icon
199
Viking Therapeutics
VKTX
$3.84B
– –
-114,016
Closed -$946K
CMRX
200
DELISTED
Chimerix, Inc.
CMRX
– –
-114,333
Closed -$494K
5 6 7
8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Tekla Capital Management held 210 positions worth $2.29B, down 6.5% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2019 filing shows 13 new, 53 increased, 56 reduced and 18 closed positions. Its largest new stake was Insmed: 164,786 shares worth $2.91M. The largest sale was Amgen, an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2019 buy was Insmed: 164,786 shares worth $2.91M.
  • Tekla Capital Management added most to Merck in Q3 2019, an estimated $16.6M increase.
  • Tekla Capital Management's biggest Q3 2019 reduction was Amgen, cutting an estimated $18.7M.
  • Tekla Capital Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $15M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.29B portfolio in Q3 2019.
  • Tekla Capital Management opened 13 new positions and closed 18 in Q3 2019.
  • Tekla Capital Management's portfolio value fell 6.5% quarter-over-quarter to $2.29B.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.